Insmed Announces First Quarter 2009 Financi...(2136 2165 Total assets ...)

Date:5/13/2009

2,136 2,165 Total assets $129,820 $4,758 Liabilities and stockholders' equity (deficit) Current liabilities: Accounts payable $2,667 $1,277 Accrued project costs & other 795 936 Payroll liabilities 5,048 453 Income taxes payable 2,794 - Restricted stock unit liability - 113 Interest payable 10 13 Deferred rent 103 168 Deferred revenue 232 302 Convertible debt 2,211 2,211 Debt discount (476) (596) Net convertible debt 1,735 1,615 Total current liabilities 13,384 4,877 Long-term liabilities: Convertible debt - 553 Debt discount - (66) Net long-term convertible debt - 487 Asset retirement obligation - 2,217 Total liabilities 13,384 7,581 Stockholders' equity (deficit): Common stock; $.01 par value; authorized shares 500,000,000; issued and outstanding shares, 124,972,146 in 2009 and 122,494,010 in 2008 1,250 1,225 Additional paid-in capital 343,817 342,378 Accumulated deficit (228,631) (346,426) Net stockholders' equity (deficit) 116,436 (2,823)
'/>"/>

SOURCE Insmed Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference